Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Dopamine vs noradrenaline: inverted-U effects and ADHD theories.

Levy F.

Aust N Z J Psychiatry. 2009 Feb;43(2):101-8. doi: 10.1080/00048670802607238. Review.

PMID:
19153917
2.

Mechanism of action of agents used in attention-deficit/hyperactivity disorder.

Wilens TE.

J Clin Psychiatry. 2006;67 Suppl 8:32-8. Review.

3.

Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms.

Stahl SM.

J Clin Psychiatry. 2010 Mar;71(3):223-4. doi: 10.4088/JCP.09bs05899pur. No abstract available.

4.

Catecholamine influences on dorsolateral prefrontal cortical networks.

Arnsten AF.

Biol Psychiatry. 2011 Jun 15;69(12):e89-99. doi: 10.1016/j.biopsych.2011.01.027. Epub 2011 Apr 13. Review.

5.

Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors.

Gamo NJ, Wang M, Arnsten AF.

J Am Acad Child Adolesc Psychiatry. 2010 Oct;49(10):1011-23. doi: 10.1016/j.jaac.2010.06.015. Epub 2010 Sep 1.

6.

Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children.

Kereszturi E, Tarnok Z, Bognar E, Lakatos K, Farkas L, Gadoros J, Sasvari-Szekely M, Nemoda Z.

Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1431-5. doi: 10.1002/ajmg.b.30704.

PMID:
18214865
7.

What do dopamine transporter and catechol-o-methyltransferase tell us about attention deficit-hyperactivity disorder? Pharmacogenomic implications.

Levy F.

Aust N Z J Psychiatry. 2007 Jan;41(1):10-6. Review. Erratum in: Aust N Z J Psychiatry. 2007 Apr;41(4):376.

PMID:
17464676
8.

Potential noradrenergic targets for cognitive enhancement in schizophrenia.

Friedman JI, Stewart DG, Gorman JM.

CNS Spectr. 2004 May;9(5):350-5. Review.

PMID:
15115947
9.

Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.

Wilens TE.

J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S46-53. doi: 10.1097/JCP.0b013e318173312f. Review.

PMID:
18480677
10.

Prepuberal subchronic methylphenidate and atomoxetine induce different long-term effects on adult behaviour and forebrain dopamine, norepinephrine and serotonin in Naples high-excitability rats.

Ruocco LA, Carnevale UA, Treno C, Sadile AG, Melisi D, Arra C, Ibba M, Schirru C, Carboni E.

Behav Brain Res. 2010 Jun 26;210(1):99-106. doi: 10.1016/j.bbr.2010.02.020. Epub 2010 Feb 13.

PMID:
20156489
13.
14.

Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways.

Arnsten AF.

J Clin Psychiatry. 2006;67 Suppl 8:7-12. Review.

15.

Atomoxetine increases histamine release and improves learning deficits in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat.

Liu LL, Yang J, Lei GF, Wang GJ, Wang YW, Sun RP.

Basic Clin Pharmacol Toxicol. 2008 Jun;102(6):527-32. doi: 10.1111/j.1742-7843.2008.00230.x. Epub 2008 Mar 16.

16.

COMT x DRD4 epistasis impacts prefrontal cortex function underlying response control.

Heinzel S, Dresler T, Baehne CG, Heine M, Boreatti-Hümmer A, Jacob CP, Renner TJ, Reif A, Lesch KP, Fallgatter AJ, Ehlis AC.

Cereb Cortex. 2013 Jun;23(6):1453-62. doi: 10.1093/cercor/bhs132. Epub 2012 May 22.

PMID:
22617852
17.

alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data.

Arnsten AF, Scahill L, Findling RL.

J Child Adolesc Psychopharmacol. 2007 Aug;17(4):393-406. Review.

PMID:
17822336
18.

Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders.

Arnsten AF, Pliszka SR.

Pharmacol Biochem Behav. 2011 Aug;99(2):211-6. doi: 10.1016/j.pbb.2011.01.020. Epub 2011 Feb 2. Review.

19.
20.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548

Supplemental Content

Support Center